Rafferty Asset Management
RNAC icon

Rafferty Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Rafferty Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-512
Closed -$19K – 1211
2022
Q1 		$19K Buy
512
+34
+7% +$2.13K ﹤0.01% 1215
2021
Q4 		$47K Sell
478
-4,700
-91% -$506K ﹤0.01% 1289
2021
Q3 		$646K Buy
+5,178
New +$625K ﹤0.01% 986

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Rafferty Asset Management's RNAC Position: Q2 2022 in Review

Rafferty Asset Management sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 512 shares — an estimated $19K sold.

Rafferty Asset Management first reported a position in RNAC in Q3 2021 and held it in 3 quarters. The position peaked at $646K in Q3 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

  • Rafferty Asset Management reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 512 Cartesian Therapeutics shares in Q2 2022, an estimated $19K.
  • Rafferty Asset Management first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 3 quarters.
  • Rafferty Asset Management's Cartesian Therapeutics position peaked at $646K in Q3 2021.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.